Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Research & Development (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Research & Development for 3 consecutive years, with $78.8 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 29.53% to $78.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $274.9 million through Dec 2025, up 23.73% year-over-year, with the annual reading at $274.9 million for FY2025, 23.73% up from the prior year.
  • Research & Development hit $78.8 million in Q4 2025 for Immunocore Holdings, up from $70.6 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $78.8 million in Q4 2025 to a low of $36.6 million in Q1 2023.
  • Historically, Research & Development has averaged $55.0 million across 3 years, with a median of $54.6 million in 2024.
  • Biggest five-year swings in Research & Development: surged 57.11% in 2024 and later decreased 1.72% in 2025.
  • Year by year, Research & Development stood at $45.6 million in 2023, then surged by 33.55% to $60.8 million in 2024, then increased by 29.53% to $78.8 million in 2025.
  • Business Quant data shows Research & Development for IMCR at $78.8 million in Q4 2025, $70.6 million in Q3 2025, and $69.0 million in Q2 2025.